Dutasteride mesotherapy: what do the studies show, and how is it different from the tablet?

I'm studying to become a cosmetologist, and my hair started falling out at 16. Dutasteride mesotherapy is often recommended as a gentler, “local” version of DHT blocking, so I collected what's been measured about it. Dutasteride inhibits both types of the 5-alpha-reductase enzyme, the enzyme that turns testosterone into DHT (dihydrotestosterone). Its EU-registered form is a 0.5 mg soft capsule, authorised according to the summary of product characteristics for symptoms of benign prostatic enlargement1. In the European Union, including Hungary, it's authorised for that indication2, and is prescribed for hair loss off-label both here and in the US. In Japan, however, the authority's 2015 assessment found it approvable for male androgenetic hair loss too, and according to the same document it's authorised for that indication in South Korea as well3. I wrote a separate article about the tablet, its side effects and where to get it: oral DHT blockers.

Mesotherapy means injecting a small amount of solution into the skin through many tiny punctures with a very thin needle. In dutasteride mesotherapy the solution goes into the dermis of the scalp, where the hair follicles sit; this is called intradermal injection. According to a 2023 short review, the technique that seems best is a series of small injections with a thin needle, about 4 mm deep4. So unlike the tablet, the drug goes into the treated skin area, and in the trials it was administered in a clinic.

The name “DHT-blocker mesotherapy” doesn't tell you exactly what's in the syringe. Of the four treated groups in the saline-controlled injection trials, three got the same kind of mixture: dutasteride with dexpanthenol, biotin and pyridoxine; only one group got pure dutasteride56. Concentration ranged between 0.005 and 0.1 percent across trials. Dutasteride dissolves poorly in water, so it needs a solvent, such as ethanol or dimethyl sulfoxide (DMSO)7. The solutions described contained ethanol and propylene glycol, or benzyl alcohol and polysiloxane (silicone)8, and there was also a water-based solution with no such solvents at all9. This matters because in some of the reported cases of patchy hair loss after treatment, the authors themselves suspect the solvent.

There's no standard treatment schedule either. The 2013 Egyptian trial gave it weekly in the first month, then every two weeks, then monthly6; from 2017 several Spanish papers used every three months1011; the tattoo-gun variant used monthly, then every two months12. A 2025 Brazilian review states that there's no standard for treatment frequency, and the choice of doses and mixtures is based on personal experience13.

What to take from this: behind the name “dutasteride mesotherapy” there can be a different active-ingredient mixture, concentration, solvent and schedule from clinic to clinic, so the name alone doesn't mean one specific treatment.

The appeal is understandable. Oral finasteride and dutasteride lower DHT throughout the whole body, and the authors of a 2026 tattoo-gun trial name fear of sexual side effects (erectile dysfunction, reduced libido, less semen) as the reasoning behind the method14. The authors of a 2022 Spanish, real-world clinical practice study say the method can be an option for those who want to avoid oral treatment11. A 2017 paper writes that frequent treatment sessions make it harder to stick with, which is why they tried a schedule given every three months10. Jeff Donovan, a dermatologist who works on hair loss, says dutasteride mesotherapy is often marketed as a “local” treatment15.

What to take from this: the promise has three parts, that it works, that the drug stays in the scalp and so causes fewer side effects, and that you don't need to go very often. There's measured data on all three, and none of them is a clear yes.

By the time of the 2020 systematic review, three trials had compared injected dutasteride with saline injections, and in all three the strongest improvement was seen in the group that got the dutasteride-and-vitamins mixture. Pure dutasteride, at a tenth of the dose used in the mixture, was given only to one 30-person group in the Egyptian trial. There, the independent evaluator saw no change on photos in seven out of ten, but no worsening in any of them either (versus three out of ten in the saline group), while hair-shaft thickness increased on the microscopic hair exam; the authors say this group also did better than the saline group, just less so than the mixture group. This data is weak: thickening was measured within each group, against their own baseline, the three groups were only tested together, and the pure-dutasteride group was never directly compared with the saline group. It can't be determined from these trials how much of the improvement is due to the dutasteride itself. The review rated all three trials as high risk of bias, meaning their design makes it quite likely that their result differs from the true effect16.

The first was a 2009 Egyptian trial. 34 men were randomised into two groups, and 28 completed it: four dropped out because of the pain of the injections, two were lost to follow-up. 14 men got a commercial cocktail containing dutasteride along with D-panthenol, biotin and pyridoxine, 14 got saline. The authors say they used this because at the time the trial started, it was the only dutasteride-containing product available in Egypt, and that pure dutasteride should be studied separately. They had seven sessions over 11 weeks, and were evaluated at week 12. The hair count in a 1 cm-diameter circle on the crown increased by an average of 7.7 hairs in the cocktail group, and decreased by 0.2 hairs in the saline group, and the difference was significant5.

The second trial was done in 2013 on 126 women with female pattern hair loss. 86 got a dutasteride-containing product, 40 got saline, 12 sessions, and were evaluated at week 18. On photos, 62.8 percent of the dutasteride group showed improvement, versus 17.5 percent of the saline group, and there was no significant difference in side effects17. I only had access to the abstract of this one. Going by the title, the product was the same dutasteride-containing mixture, and according to a 2025 paper's table it had the same ingredients as in the first trial: dexpanthenol, biotin and pyridoxine8. According to the abstract, patients were split into two groups; it doesn't mention randomisation.

The third trial, also from 2013 and Egyptian, involved 90 men in three groups of 30. One group got pure dutasteride, another got the same commercial cocktail as in the 2009 trial, the third got saline, nine sessions over 19 weeks. Photos were scored by an independent evaluator. Of those on pure dutasteride, 70 percent showed no change, 20 percent mild, 10 percent moderate improvement. Of those on the cocktail, 40 percent showed mild, 40 percent moderate improvement, 20 percent no change. In the saline group, 30 percent worsened, 40 percent showed no change, 30 percent improved mildly. On microscopic exam of plucked hairs (trichogram), average hair-shaft thickness increased significantly compared with baseline in both treated groups, only mildly and not significantly in the saline group; the proportion of hairs in the growth phase, however, increased significantly only in the cocktail group. The authors say the improvement was not clinically striking in either treated group, and patients' own assessment did not differ significantly between the three groups6.

In this trial, the group that got the cocktail received roughly ten times as much dutasteride per session as the pure-dutasteride group: by the authors' calculation, 0.75–1 mg versus 0.075–0.1 mg6. So the larger dose and the vitamins may both explain the better result.

What to take from this: the clearest improvement in all three trials was in the group that got dutasteride mixed with vitamins. In the one group that got pure dutasteride, hair shafts thickened, but seven out of ten showed no change on photos (and no worsening at all, versus three out of ten in the saline group), and this data has no head-to-head comparison. All three trials are small and at high risk of bias.

Saceda-Corralo and colleagues in 2017 gave low-dose dutasteride, about 0.1 mg per session, to six patients (five men and one woman), every three months, three times in total. Nine months after the first session, hair density and hair-shaft thickness had increased in all six patients on trichoscopy, a magnifying-camera exam, and blood hormone levels hadn't changed. The authors themselves write that the sample is small and follow-up short10. There was no control group.

The same author and Spanish colleagues reviewed the charts of 541 patients retrospectively in 2022, from several clinics. In the first year, the most common schedule was every three months. The most common side effect was pain, in 246 patients (45.5 percent); no serious or sexual side effects were observed. The effect, however, could only be judged in 86 patients (15.9 percent) after one year without any other treatment added; most of them showed improvement, marked improvement in 33 (38.4 percent)11. The abstract doesn't say why it couldn't be judged in the rest; I didn't have access to the full text.

A New York dermatology group described ten patients (four men and six women) in 2024, who got a sterile, pharmacy-compounded, water-based dutasteride solution without propylene glycol, ethanol or DMSO, roughly every three months. Compared with baseline, neither hair count nor hair-shaft thickness changed significantly, either at the hairline or the crown, and none of them reported a side effect. All of them were also on another hair-loss treatment, started at least four months earlier. The authors say the infrequent dosing may explain the result, but they also raise the possibility that the lack of a clear improvement may also indicate a lack of effect9.

A randomised trial on Brazilian men was published in 2026, comparing monthly and quarterly dutasteride mesotherapy; the group treated every three months got a placebo at the sessions in between18. I didn't have access to the full text of this paper, so I'm not citing a number from it. According to Donovan's summary, there was no meaningful difference between the two schedules; overall hair density improved slightly, thick, fully mature (terminal) hairs did not15. Since both groups got dutasteride, this trial measures whether the less frequent session is as good as the more frequent one. It doesn't measure how much better either is than nothing.

A 2022 retrospective letter on 105 men studied dutasteride injection together with oral minoxidil19. I didn't have access to the full text, and because it's a combination, dutasteride's own share can't be separated out of it. If you read percentages from this trial, I couldn't trace them back to the primary source.

What to take from this: the uncontrolled case series describe improvement in some, no change at all in others, and in the largest, 541-person body of data, the effect could only be judged on its own in 86 patients.

There's no head-to-head trial between the tablet and mesotherapy. The authors of the 2020 systematic review didn't find one16, and neither did I find a more recent one. Placing the placebo-controlled trials side by side, the authors say a clear difference favours oral dutasteride, but the two routes couldn't be compared statistically, and until there's more evidence, doctors should be cautious before recommending mesotherapy as a better alternative to the oral form16. This comparison stands on shaky ground. On the injection side there was a single trial reporting hair count, and even that used the vitamin cocktail, after 12 weeks and on a different measurement area, counted in a 1 cm-diameter circle5; the tablet trials ran at least 24 weeks16.

The 2024 consensus (expert agreement) of the Spanish dermatology society's hair disorders group placed oral dutasteride first-line for men, with level 1a evidence and grade A recommendation. It placed dutasteride mesotherapy second-line for both men and women, with level 2b evidence and grade C recommendation20. On this scale, 1a and A are the strongest grade. First-line is what a doctor starts with, second-line is what they turn to if the first doesn't work, or doesn't suit the patient. The same consensus also writes that among the agents used in mesotherapy, 0.01 and 0.05 percent dutasteride showed the greatest effect in the trials, but for several mesotherapy recommendations no consensus was reached, due to a lack of scientific evidence20. The consensus's first author, Vañó-Galván, is also a co-author of the 2017 pilot above10.

Later reviews say the same. A 2023 systematic review on mesotherapy for hair loss in general says several trials report significant improvement, but there's no standardised treatment regimen, and side effects have also been described21. A 2026 systematic review covering 30 papers says injection treatment can offer cosmetic benefit, especially with dutasteride, but the evidence is limited by small sample sizes, differing protocols and short follow-up, and standardised randomised trials are needed before it can be recommended routinely22. Saceda-Corralo, first author of the pilot above and the 541-person body of data, wrote himself with colleagues in 2023 that the efficacy evidence is limited to retrospective, real-world clinical practice studies23.

There's also a 2025 meta-analysis, meaning an analysis that statistically pools the numbers from several trials, which calls the method promising. I'm not citing its numbers, because they contradict each other internally: for terminal hair count it calls a result significant whose confidence interval (the uncertainty range of the estimate) also spans zero, and its table misrepresents the design of at least one earlier trial24.

Ask your doctor this: what argues for mesotherapy over the tablet in my case, if most of the controlled improvement came from a vitamin mixture, the indirect data points to the tablet being stronger, and even the Spanish consensus only places it second-line?

I found no trial that measured blood dutasteride levels after mesotherapy. What has been measured is the change in hormone levels and sperm values, and these point in two directions.

In the six-person pilot, where about 0.1 mg of dutasteride went in per session, every three months, hormone levels measured before and after treatment didn't differ. The authors note in the same paper that because of the scalp's strong blood supply, some believe absorption is the same as with the tablet, and their own result shows that with a non-intensive schedule, absorption is negligible10. In the tattoo-gun trial, four of the eight participants got dutasteride; the authors say there was no clinically meaningful change in lab values, including DHT, and they don't report numbers14.

In the cocktail group of the 90-person Egyptian trial, where 0.75–1 mg of dutasteride went in per session, nine sessions, two men (one aged 27 and one 40) had their sperm concentration drop from 29 million to 7 million per millilitre, and from 30 million to 10 million per millilitre respectively, motility also dropped, and it recovered to nearly the baseline value after three months. At group level there was no significant difference in sperm values, but the authors say a decreasing trend appeared in both treated groups, including the low-dose, pure-dutasteride one: in semen volume in the pure-dutasteride group, in sperm concentration in the cocktail group, and in motility in both. They assessed that some degree of systemic, meaning whole-body, absorption had occurred. The authors themselves call the blood DHT measurement contradictory and unreliable. Their conclusion is that systemic absorption and an adverse effect on sperm production is possible, especially with an unlimited number of injections, and they don't recommend the method for those planning a child, those with borderline or abnormal sperm parameters, or those with erectile or ejaculatory dysfunction6.

About the 2026 Brazilian trial, Donovan writes that it showed signs of systemic absorption, because blood DHT levels also dropped, and one participant withdrew due to reduced libido and depressive symptoms15. I didn't have access to the primary paper, so I'm not citing a number from it. For oral dutasteride, the European Medicines Agency's 2025 review found no direct link to suicidal thoughts, but because it works the same way as finasteride, a warning about mood changes is added to dutasteride's product literature out of caution too; for finasteride, this side effect was confirmed2. The capsule's UK summary of product characteristics already states that with another oral 5-alpha-reductase inhibitor, low mood, depression and, more rarely, suicidal thoughts have been reported1. I described the reported case numbers together with the patient-years behind them in the article on oral DHT blockers.

For sexual side effects, “not reported” isn't the same as “didn't happen.” According to the 2020 review, none of the injection trials reported a libido-related side effect16, and the 541-person Spanish body of data is a retrospective chart review, where what's recorded is what was written down11.

The mesotherapy papers justify the every-three-months schedule by dutasteride's long half-life. Half-life is the time it takes for the amount in the body to drop by half. The capsule's summary of product characteristics, however, says the 3–5-week half-life applies to repeated, daily 0.5 mg dosing; for a single dose of up to 5 mg, clearance is faster, and the half-life is 3–9 days1. I found no measurement of how dutasteride injected into the skin clears, so the argument that “infrequent is enough because it stays in the body a long time” rests on tablet data. The Spanish consensus doesn't recommend drug-based mesotherapy in pregnancy either, precisely because of possible systemic absorption20.

What to take from this: the claim that it “only acts locally” rests on unchanged hormone levels measured in a few patients. In the 90-person trial, a decreasing sperm trend was described even in the low-dose, pure-dutasteride group, a strong sperm drop in two men on the higher dose, and a DHT drop in a 2026 trial, so it's worth reckoning with the possibility that the drug can also reach the bloodstream.

The most common is pain. In the 541-person Spanish body of data it occurred in 45.5 percent of patients11, and in the 2009 Egyptian trial, four of the 34 men enrolled stopped treatment because of the pain of the injections5. A 2025 Brazilian review says it can be eliminated with anaesthesia (a nerve block), and more rarely swelling of the forehead or face, or bruising, can also occur13. In a 2022 series describing 14 cases, forehead oedema (fluid swelling) mostly appeared after the first two sessions, lasted 1–4 days, and resolved with cold compresses. In every case, lidocaine was used for anaesthesia, and the authors say both minoxidil and dutasteride may play a role25. The 2026 review describes side effects as generally mild, but they include paradoxical hair loss, scarring and acute dermatitis22.

Mesotherapy can also cause infection, if the injected material or the device is contaminated. A 2022 systematic review found 423 patients across 30 papers who developed skin infections after mesotherapy, caused by non-tuberculous mycobacteria, environmental relatives of the tuberculosis pathogen. These infections come from environmentally contaminated injections, and often involve scarring and prolonged treatment26. In a French outbreak, the investigation found the infection could be linked to tap-water cleaning of a multi-puncture device27, and in a Spanish outbreak, 17 of 77 treated people became infected, with the most likely source being an injectable product contaminated at the factory28. Multifocal abscess, subcutaneous fat necrosis and scarring hair loss after scalp mesotherapy have also been described, requiring extensive surgical repair29. Most of these cases come from mesotherapy performed on other parts of the body, and none were linked to dutasteride; I found no reported scalp infection after dutasteride mesotherapy.

The US Centers for Disease Control and Prevention (CDC) investigated a prolonged skin reaction in 14 patients after mesotherapy by an unlicensed provider in 2005, and recommended that patients only accept treatment from a licensed provider, and not allow a substance not approved by the US Food and Drug Administration (FDA) to be injected into them30.

What to take from this: pain is common, swelling lasting a couple of days can occur, and infection risk depends on how sterile the injected material and the treatment are.

Yes, according to case reports. At least five papers describe at least 14 cases where patchy or extensive hair loss appeared after dutasteride-containing mesotherapy. This includes cocktails that had dutasteride together with other active ingredients, just as in the improvement-showing trials above.

In a 2022 paper, a woman developed patchy hair loss at the injection sites one month after a single session, and a man developed several atrophic (shrunken) bald patches; in his case there was no improvement after three months of 5 percent minoxidil either. The solution contained ethanol and propylene glycol, and the authors' hypothesis is that the ethanol may have damaged the hair follicles7.

In a 2025 Indian series, 4 of 15 treated people developed non-scarring, patchy hair loss at the injection site after a single session. The solution also contained benzyl alcohol and polysiloxane, which the authors suspect of being cytotoxic, and they call for stricter regulatory oversight of the manufacture of mesotherapy cocktails. In two described patients, hair regrew within three months with treatment: in one with a steroid injected into the patch, in the other with an immune-response-suppressing tablet (tofacitinib). In the third, regrowth was only partial after the steroid injection into the patch, and in the fourth, hair on the crown kept thinning even after two months of drug treatment alone8.

In a 2026 series, three women were left with a persistent bald patch. Two showed signs of scarring hair loss: in one, confirmed on biopsy, with only partial improvement and later requiring surgical correction; in the other, the magnifying-camera exam showed a mixed picture, with limited regrowth. In the third, the bald patch persisted despite corticosteroid and adjunct treatments. None of them had full hair regrowth, and the authors say this complication may not always be recognised31.

A 2026 paper describes three cases where sudden, extensive hair loss, known as anagen effluvium, appeared after dutasteride mesotherapy: in two after a single session, in the third after a treatment six weeks earlier. In this condition, hairs in the growth phase fall out. All three patients felt strong pain during treatment, the solution was alcohol-based, and hair grew back fully on its own within 4–6 months. The authors don't recommend alcohol-based dutasteride mesotherapy32.

A 2017 paper described hair loss at the injection sites in three patients, even after up to a year of previously uneventful treatment; the findings suggested scarring inflammation, and the authors say mesotherapy can paradoxically cause both hair loss and scarring33. I didn't have access to the full text of this paper; according to two later papers, at least two of them also had 0.005 percent dutasteride in the cocktail, alongside growth factors, copper peptide and vitamins78. In 2009, patchy hair loss after scalp mesotherapy without dutasteride was also described34.

What to take from this: there's no reliable figure for how often patchy hair loss occurs after treatment, but it's documented, and in several cases the authors suspect the solvent. If your hair starts falling out in patches after treatment, see a dermatologist.

I couldn't find an injectable dutasteride product registered anywhere. The only form in the US summary of product characteristics is the 0.5 mg soft gelatin capsule35, and the European Medicines Agency's 2025 EU-wide review also only discussed the 0.5 mg capsule2. A 2024 and a 2025 paper say dutasteride mesotherapy hasn't been approved by the FDA, and is used off-label98. A Canadian dermatologist writes that there's no factory-made, registered sterile dutasteride solution in Canada, so providers have to rely on pharmacy compounding36. An experimental, quarterly intramuscular dutasteride injection is in trials, with a phase 3 trial recruiting in South Korea; this goes into muscle, not the scalp, and there's no result yet37.

The capsule is contraindicated in women and children. Because dutasteride absorbs through the skin, according to the summary of product characteristics, women, children and adolescents must not even touch the leaking capsule, and if they do, the skin should be washed immediately with soap and water1. I found no regulatory document for mesotherapy. Trials have also been done on women, and some of the persistent hair-loss cases were also in women31, and according to the Spanish consensus's expert-opinion recommendation, premenopausal women on dutasteride must use contraceptive pills during treatment and for up to 6 months after stopping20.

What to take from this: whoever injects dutasteride into the scalp is using a solution compounded at a pharmacy or by a manufacturer, not a registered one, so it's always a question who made it and from what.

I found a single published randomised, placebo- and active-controlled trial of topical dutasteride applied to the skin without a device. A 2025 Indian phase II trial (the second stage of drug development, where effect and dose are being explored) involved 135 men aged 20 to 60, with thinning at the crown between Norwood grade III and V (the scale describing the stages of male hair loss). Over 24 weeks they got once-daily 0.01, 0.02 or 0.05 percent dutasteride solution, or 1 mg oral finasteride, or placebo. The solution was applied with a dropper to a 1.9 cm² area on the crown, and hair count was counted in a 1 cm² target area40.

At week 24, the 0.05 percent solution gave significantly more hair in the target area than oral finasteride, and this was the trial's primary endpoint. Versus placebo, the 0.01 and 0.05 percent solutions were significantly better, the 0.02 percent one wasn't, so the effect didn't scale evenly with concentration. Blood testosterone and DHT levels didn't change significantly; DHT was 8.9 percent lower at week 12 and 11 percent lower at week 24 in the dutasteride group. Most measured blood levels were around or below the limit of detection, but the authors say detectable levels even on day 168 indicate prolonged systemic exposure. The authors reported no side effects, but scalp shininess, and in some, flaking and cracking, were described in every group40.

The trial was funded by the manufacturer, Shilpa Medicare, and every author is an employee of the company. Only a small patch was treated and measured, so neither the effect nor the absorption can be extrapolated to the whole scalp. It was done on a single ethnicity, Indian men, ran for 24 weeks, and I found no follow-up phase III trial.

A Spanish, hospital-sponsored phase II trial on 45 men compared a 0.15 percent dutasteride emulsion with the vehicle; it concluded in 2023, but I found no result from it41. A South Korean trial will measure local dutasteride blood levels, but hasn't started recruiting yet42. The 2025 Brazilian review says dutasteride's large molecule size makes it hard to formulate as a topical product, and there's currently not enough data for its use13. Another 2025 review warns that rodent skin and thinly sliced skin samples are much more permeable than pig or human skin, so such models overestimate how much dutasteride passes through the skin43. The Spanish consensus places 0.5–1 percent topical dutasteride second-line too, again with level 2b evidence and grade C recommendation20; this concentration is ten to a hundred times what the Indian trial tested, and I found no randomised trial at this concentration.

I found no approved, skin-applied dutasteride drug. The European Medicines Agency's 2025 review discussed the topical spray for finasteride, but for dutasteride, only the capsule2. Keeps, a US company, sells an 11-ingredient, pharmacy-compounded topical drop containing dutasteride and minoxidil under the name Drop+, according to its own site (checked 26 September 2026), and states itself that the product isn't FDA-approved44. The site doesn't name the concentration or the other nine ingredients, and I found no trial for this mixture. The site states that dutasteride blocks DHT more effectively than finasteride; this is data measured at oral doses, and for the topical, device-free form there's a single published randomised trial, also manufacturer-run.

I found no regulatory warning specifically about topical dutasteride. For the related active ingredient, finasteride, the US Food and Drug Administration warned in April 2025: pharmacy-compounded topical finasteride has no FDA-approved form, entry into the bloodstream through the skin is expected, some patients were told by their prescriber that the topical form carries no risk, and there's a separate risk that the applied product can transfer to others, especially women45. The warning doesn't mention dutasteride. I wrote about the details in the article on finasteride and minoxidil combinations, and about the topical finasteride spray in the article on topical finasteride.

What to take from this: for topical, device-free dutasteride there's a single published randomised, manufacturer-run trial on a small patch of skin, where the drug was also detectable in the blood, and there's no approved product.

Dutasteride has also been delivered into the skin with a device, and these trials are all clinical and small. The tattoo-gun variant, microinfusion (MMP), is widespread in Brazil: the device uses a sterile, multi-needle cartridge to puncture tiny channels while delivering the solution into the skin. According to the 2025 Brazilian review, until then only case reports had been published on this13.

In the first placebo-controlled MMP trial, published in 2026, eight men got three monthly sessions, four got dutasteride, four got saline, with needle depth set to 1.0 mm. Photos were assessed by three dermatologists blinded to group assignment, and there was no statistical difference between the two groups; by the patients' own assessment, however, there was marked improvement at the crown in the dutasteride group. The authors call both treatments effective, including the tattooing without drug, even though by their own sample-size calculation 32 participants would have been needed14.

In a 2026 Italian, uncontrolled series, 30 men got four monthly MMP sessions, then a maintenance session every two months, at 1.0 mm depth, and after 12 months, 76.7 percent had clinical improvement described. The author himself writes that controlled trials are needed12. Without a control, natural fluctuation and the effect of the tattooing itself can't be separated from dutasteride's.

In two retrospective series, a tattoo gun delivered minoxidil and dutasteride, or these plus copper peptide, with 1.5 mm and 2 mm needle depth respectively. Without a control group, compared with baseline, more than 10 percent improvement in crown coverage was described in 8 of 15 men, and 5 of 7 respectively; the first series analysed the 15 men, out of 73 who got at least one treatment, who got all three monthly sessions4647. Because it's a combination, dutasteride's own effect can't be read out of these, and in the first series patients may also have been taking an oral 5-alpha-reductase inhibitor.

In a 2022, 20-week, double-blind, placebo-controlled trial, 0.01 percent dutasteride solution or saline was applied after clinical microneedling48. Here the control group also got the microneedling, so the trial measures the added benefit over the microneedling itself. I didn't have access to the full text; according to a Canadian dermatologist's summary, hair density improved more in the dutasteride group36. With dutasteride applied after fractional CO2 laser (a laser that burns tiny columns into the skin), better improvement was described on 15-and-15 men than with the laser alone49. With iontophoresis, meaning delivery aided by a mild current, improvement was described in a 20-person, uncontrolled pilot in patients where the usual treatment hadn't worked over at least 12 months50.

What to take from this: every device-based data point comes from a clinic, with a clinical device and a sterile solution, and the control group mostly also got tattooing. I found no trial of dutasteride delivered with a home dermaroller, dermapen or stamp.

No, and there are specific reasons for that.

The first is the active ingredient. The trials used a sterile solution compounded at a pharmacy or sourced from a manufacturer910, and there's no registered injectable or topical dutasteride. Dutasteride dissolves poorly in water, it needs a solvent7, and in several reported cases of patchy hair loss after treatment, the authors suspect the solvent itself832. With a solution mixed at home, you can't know the concentration, the sterility, or the solvent's effect.

The second is absorption. Dutasteride also absorbs through the skin1, and I found no trial of how much dutasteride applied after needling reaches the skin and the bloodstream. Opening the capsule is exactly the kind of contact the summary of product characteristics forbids for women, children and adolescents.

The third is infection and reaction. The mesotherapy infection outbreaks started from contaminated material or a poorly cleaned device2728. A foreign-body reaction, called a granuloma, has also been described after applying a skincare product not meant to go into the skin before microneedling, and the authors specifically point out that the microneedling device is also available at home51.

The fourth is that the device-based trials were all done with a clinical device, in a medical setting, and patchy hair loss after treatment was described following clinic-administered dutasteride mesotherapy.

If you decide to try it with a doctor, these questions follow from the facts above.

Ask this at the clinic:

• Does a doctor administer the treatment?
• Exactly what's in the syringe: pure dutasteride or a solution mixed with other active ingredients, and at what concentration?
• What's the solvent? Does it contain ethanol, propylene glycol or benzyl alcohol?
• Who compounded the solution, and is it sterile? There's no registered injectable dutasteride, so this is always a compounded solution.
• How many sessions, at what intervals, and what is that based on?
• What should I do if my hair starts falling out in patches after treatment?
• We're planning a child, or I'm a woman and could become pregnant: what does that mean for me?

Microneedling is a mechanical stimulus with no hormonal effect, so it can be added alongside drugs that act on DHT. The Dermastamp is a fixed 1 mm, at-home device: the needle stimulates the area around the follicle, and doesn't touch DHT through its mechanism. This is inferred from the mechanism, not measured. You don't skip oral finasteride or dutasteride on the day you stamp. With scalp-applied products, stamping day is a pause, and the exact timing differs by product: the timing of actives. For anyone who doesn't want to touch their hormones, this is a route that stays available, with one limitation: in the study measuring the combination, both groups also received minoxidil, and the study used a 1.5 mm clinical roller, not our fixed 1 mm device; there's less data on it used alone. What it can do, what it can't, and who it's not for: I've written it all on its page.

See the Dermastamp